Gentamicin Dosing Calculator

Gentamicin dosing is driven by which weight goes into the equation. Ideal body weight comes from the Devine formula, 50 kg for a man or 45.5 kg for a woman plus 2.3 kg for every inch above 60, and that figure is used directly unless actual weight exceeds it by more than 20 percent, at which point adjusted weight of ideal plus 0.4 of the excess applies. The chosen weight then feeds both the dose, 5 to 7 mg/kg for extended-interval therapy, and the Cockcroft-Gault clearance estimate, from which the elimination rate constant follows as 0.00293 x CrCl + 0.014 and the estimated peak as dose divided by a distribution volume of about 0.25 L/kg. Target concentrations differ sharply by indication and must not be conflated. Extended-interval therapy for serious gram-negative infection aims for a peak of roughly 15 to 25 micrograms/mL with a trough that is undetectable or below 1. Synergy dosing for enterococcal or streptococcal endocarditis uses only about 1 mg/kg every 8 hours with peaks of 3 to 4, because the aim is to help a cell-wall agent penetrate rather than to kill independently. Dosing intervals stretch with declining clearance, conventionally 24 hours above 60 mL/min, 36 hours from 40 to 59, and 48 hours from 20 to 39, with individualised kinetics below that. Gentamicin injures the vestibular apparatus more than the cochlea, so unsteadiness and oscillopsia matter as much as audiometry, and that damage is frequently permanent even though the accompanying tubular nephrotoxicity usually resolves. Extended-interval prediction is unreliable in burns, ascites, cystic fibrosis and pregnancy.

Gentamicin was isolated in 1963 by Marvin Weinstein and colleagues at the Schering Corporation in New Jersey from Micromonospora purpurea, a soil bacterium. Because the producing organism is a Micromonospora rather than a Streptomyces, the compound was spelled with an i in the suffix, gentamicin rather than gentamycin, a convention that still distinguishes members of the class by their genus of origin. Approved in the mid-1960s, it filled an urgent gap: it was among the few agents active against Pseudomonas aeruginosa at a time when serious gram-negative sepsis had few effective treatments. Dosing method developed only after the toxicity became apparent. Ben Devine published his ideal body weight formula in Drug Intelligence and Clinical Pharmacy in 1974 specifically in the context of gentamicin therapy, and it has since been borrowed for dozens of unrelated drugs. Sarubbi and Hull provided the creatinine-clearance-based kinetic method in 1978. The decisive practical change came with once-daily administration: David Nicolau and colleagues implemented and audited a 7 mg/kg extended-interval programme at Hartford Hospital in Connecticut in the 1990s, publishing results in a cohort of more than two thousand patients and producing the single-level nomogram, sampled between 6 and 14 hours post-dose, that bears the hospital's name. The arrival of broad-spectrum beta-lactams and fluoroquinolones later narrowed gentamicin's role, but rising carbapenem resistance has returned it to use as a targeted and combination agent.